Mesoblast Ltd.
- Country
- 🇦🇺Australia
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 73
- Market Cap
- -
- Website
- http://www.mesoblast.com
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
- Conditions
- Degenerative Disc Disease
- Interventions
- Drug: Saline
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT06325566
- Locations
- 🇺🇸
Boomerang Health Care, Concord, California, United States
🇺🇸Colorado Spine Partners/The Denver Spine and Pain Institute, Greenwood, Colorado, United States
🇺🇸Eximia EquiHealth Research LLC, Durham, North Carolina, United States
Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain
- Conditions
- Degenerative Disc Disease
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 404
- Registration Number
- NCT02412735
- Locations
- 🇺🇸
Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
🇺🇸Tennessee Valley Pain Consultants, Huntsville, Alabama, United States
🇺🇸Arizona Pain Specialists, Scottsdale, Arizona, United States
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
- Conditions
- Acute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaNon-Hodgkin's LymphomaHodgkin's Disease
- Interventions
- Biological: Infusion of one MPC expanded cord unit and one unexpanded cord unitBiological: Infusion of two unexpanded cord blood units.
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT01854567
- Locations
- 🇺🇸
University of Miami Health System Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Normal Saline
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT01851070
- Locations
- 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸Arthrocare Arthritis Care and Research PC, Gilbert, Arizona, United States
🇺🇸Triwest Research Associates, El Cajon, California, United States
Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy
- Conditions
- Diabetic NephropathyType 2 Diabetes
- Interventions
- Biological: Mesenchymal Precursor Cells (MPCs)
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT01843387
- Locations
- 🇦🇺
Monash Universtiy, Clayton, Australia
🇦🇺Melbourne Renal Research Group, Melbourne, Australia
Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT01576328
- Locations
- 🇺🇸
SC Clinical Research, Garden Grove, California, United States
🇺🇸Diabetes Research Institute, Miami, Florida, United States
🇺🇸Compass Research, Orlando, Florida, United States
Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain
- Conditions
- Degenerative Disc Disease
- Interventions
- Biological: Single Dose MPCs InjectionProcedure: Single injection of saline solutionProcedure: Single injection of hyaluronic acid
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT01290367
- Locations
- 🇺🇸
Arizona Pain Specialists, Scottsdale, Arizona, United States
🇺🇸UC Davis Spine Center, Sacramento, California, United States
🇺🇸The Spine Institute, Santa Monica, California, United States
Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion
- Conditions
- Spinal StenosisCervical Degenerative Disc DiseaseDegenerative Spondylolisthesis
- Interventions
- Biological: NeoFuseDevice: MasterGraft Granules
- First Posted Date
- 2010-04-19
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT01106417
- Locations
- 🇦🇺
Monash Medical Centre, Clayton, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Melbourne, Victoria, Australia
Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy
- Conditions
- Spinal StenosisDegenerative SpondylolisthesisCervical Degenerative Disc Disease
- Interventions
- Procedure: AllograftBiological: NeoFuse
- First Posted Date
- 2010-04-01
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT01097486
- Locations
- 🇺🇸
UC Davis Spine Center, Sacramento, California, United States
🇺🇸The Spine Institute, Santa Monica, California, United States
🇺🇸Denver Spine, Denver, Colorado, United States
Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction
- Conditions
- Anterior Cruciate Ligament InjuryOsteoarthritis
- Interventions
- Biological: MSB-CAR001 Combined With Hyaluronan
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT01088191
- Locations
- 🇦🇺
Emeritus Research, Malvern East, Victoria, Australia